IRIDEX Q1 2026 revenue declined 1% to $11.8M; net loss narrowed to $0.5M

Iridex reported flat revenue with Cyclo G6 glaucoma product growing 14% offset by retina product decline, while net loss improved significantly year-over-year. The company affirmed 2026 guidance and expects cash flow positive results this fiscal year as cost reduction initiatives take effect.